Besides myocardial necrosis, hs-cTnT assays can be detectable in COVID-19 as the consequence of the transient ischemic or inflammatory conditions associated with the disease, including respiratory and renal failure, hypoxemia, tachyarrhythmias and thrombo-embolic disease [35]. This evidence concerns the gene TNNT2 and COVID-19.